| Name | Title | Contact Details |
|---|
Unlike traditional approaches that only address symptoms, Cardionomic addresses the conditions root cause of reduced contractility. The therapy uses neuromodulation to benignly increase contractility, thus improving cardiac output therefore increasing renal flow and end organ perfusion. Benignly increasing contractility decreases negative hormonal signaling, and improves in-hospital morbidity/mortality. This breakthrough therapy is also expected to increase pharmacological tolerance at discharge, which will reduce costly readmission and extend life. Spun off from Denali Medical II, a New Enterprise Associates (NEA) backed incubator, Cardionomic is funded by NEA, Greatbatch Medical and Cleveland Clinic Foundation.
Health Solutions Plus is a Melville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Carefx Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
MEDO USA is a Roselle, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Richman Root Delaney MD is a Waterford, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.